Belantamab Mafodotin

adc

Identifier: CI-DRUG-00000768
Entity page: /drug/belantamab-mafodotin ↗
Edges: 93

Neighbours: 7 cancers16 genes10 trials2 approvals
Drawn: 35 of 35 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Belantamab Mafodotin approved for …APPROVED_FOR4 of 2
→ approved for	Multiple Myelomahematologic_malignancy	supports	FDA ORIG	Multiple Myeloma	1	Regulatory	openfda	graph →
→ approved for	Multiple Myelomahematologic_malignancy	supports	EMA indication text

Belantamab Mafodotin targets …TARGETS16 of 16show fewer
→ targets	TUBA3E	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB2A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB2B	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB6	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA1B	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA1C	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA1A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB3	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB4A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB8	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA3C	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA4A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TNFRSF17	—	BINDING AGENT	—	1	Curated	chembl	graph →
→ targets	TUBB4B	—	INHIBITOR	—	1	Curated	chembl	graph →

Belantamab Mafodotin targets …TARGETS16 of 16show fewer

→ targets

TUBA3E

—

INHIBITOR

—

Curated

Belantamab Mafodotin investigated for …INVESTIGATED_FOR2 of 2
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Multiple Myelomahematologic_malignancy	unknown	4	Multiple Myeloma	1	Curated	chembl	graph →

Belantamab Mafodotin investigated in trials for …INVESTIGATED_IN_TRIALSderived7 of 7
→ investigated in trials for	Multiple Myelomahematologic_malignancy 58 trials (38 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Multiple Myeloma	58	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasmcancer_family 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Plasma Cell Neoplasm 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Plasma Cell Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	AL Amyloidosis 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	AL Amyloidosis	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Amyloidosis 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Amyloidosis	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Plasmablastic Lymphoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Plasmablastic Lymphoma	1	Observed	clinicaltrials	graph →

Belantamab Mafodotin studied in …STUDIED_INderived10 of 66show all (up to 200)
→ studied in	NCT05874193Phase 2 · withdrawn A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma · 66 trials list this drug (42 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04876248Phase 2 · active not recruiting Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant · 66 trials list this drug (42 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05789303Phase 2 · recruiting Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma · 66 trials list this drug (42 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05208307Phase 2 · recruiting Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma · 66 trials list this drug (42 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06232044Phase 1/Phase 2 · suspended Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma · 66 trials list this drug (42 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07227311Phase 2 · recruiting A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) · 66 trials list this drug (42 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05145816Phase 1/Phase 2 · recruiting Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis · 66 trials list this drug (42 active)	—	—	AL Amyloidosis,Amyloidosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT05714839Phase 1/Phase 2 · recruiting A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments · 66 trials list this drug (42 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07285239Phase 3 · recruiting Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma · 66 trials list this drug (42 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05091372Phase 2 · recruiting Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma · 66 trials list this drug (42 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths